174: How Do We Fix the Bias in Biomedical AI Podcast with Victor CEO and Founder of Omica.Ai

Why are billions of people still invisible in genomic research—and what does that mean for the future of precision medicine?

In this episode, I sit down with Victor Angel Mosti, founder and CEO of Omica.Ai, for one of the most insightful conversations I’ve recorded about data equity and building ethical, community-centered AI.

Victor shares not only his personal cancer story but also the staggering truth: Hispanic and Latino populations make up less than 1% of genomic datasets. This underrepresentation isn’t just a data gap—it’s a clinical risk.

We dive into disparities between healthcare systems, the promise of digital pathology as a low-cost entry point, the dangers of “parachute science,” and how Victor is building a living, ethical, transparent biobank through Omica. AI—built for true precision medicine rooted in community trust.

Highlights with Timestamps

• [00:00–01:40] Personal cancer experiences and diagnostic uncertainty
• [01:40–06:50] Victor’s medical journey across Mexico and the U.S.
• [06:50–11:42] The digitization gap: empathy vs. tech
• [11:42–16:43] The “coffee diversity” metaphor for genomic diversity
• [16:43–19:34] Funding disparities & the biotech cold-start problem
• [19:34–25:44] Digital pathology as a gateway to precision medicine
• [25:44–31:44] Avoiding “parachute science” and building community-first research
• [31:44–36:05] The Nagoya Protocol and benefit-sharing
• [36:05–41:47] Omica.Ai’s work, goals, and clinical-embedded approach
• [41:47–49:36] Creating future-proof, embedded biobanks
• [49:36–53:35] Blockchain for transparency and patient trust
• [53:35–54:39] Victor’s call to action: collaborate, include, and stay human
  
  

Resources from This Episode

• Omica.Ai – Community-driven precision medicine platform
• Nagoya Protocol – Framework for equitable biological use
  
  

Key Insights

• Cancer is personal—even for experts
• <1% representation of Latino genomes threatens clinical accuracy
• Digital pathology + AI can leapfrog infrastructure gaps
• Ethical biobanking requires trust, transparency, and local benefit
• Avoiding “parachute science” is essential
• Genetic diversity drives discovery—but only if we capture it
• Blockchain + dynamic consent = future of patient-centered data